USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: ELCATECH, INC.
Address: 101 N CHESTNUT STREET
Winston-salem, NC 27101
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $758,168.00 12
SBIR Phase II $1,979,460.00 4

Award List:

ELCATECH HAS DEVELOPED A NEW TECHNIQUE FOR THE IMMUNOASSAY OF CLOTTING FACTORS.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: George j doellgast , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Elcatech has developed a new technique for the immunoassay of clotting factors. the technique is similar to the elisa methodology in that enzyme-labeled derivatives of antigens and antibodies are used to detect immune complexes. it differs from most elisa methods in that it uses an activatorof… More

ELCA ASSAY OF CLINICALLY IMPORTANT CLOTTING FACTORS

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: George J Doellgast , Principal Investigator
Award Amount: $50,000.00

ELCA ASSAY OF CLINICALLY IMPORTANT CLOTTING FACTORS

Award Year / Program / Phase: 1987 / SBIR / Phase II
Agency: HHS
Principal Investigator: George J Doellgast , Principal Investigator
Award Amount: $253,000.00
Abstract:
A new technique has been developed to assay clotting factors: solid-phase fibrinogen and labelled fibrinogen together are used as a substrate to detect thrombin genera- ted from the clotting cascade. when thrombin cleaves both forms of fibrinogen to fibrin, the labelled fibrin in solu- tion… More

A UNIQUE ENZYME LINKED FIBRINOLYTIC ASSAY SYSTEM

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

A UNIQUE ENZYME LINKED FIBRINOLYTIC ASSAY SYSTEM

Award Year / Program / Phase: 1989 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $500,000.00
Abstract:
Thrombolytic therapy has become an increasingly important tool in the treatment of acute myocardial infarction. the most recently approved therapeutic agent for this purpose ist-pa (tissue plasminogen activator) which has the advantagesof being fibrin specific and is rapidly cleared in vivo by the… More

A STAINING METHOD FOR ELECTROPHORETICALLY SEPARATED CLOTTINGFACTORS

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: George J Doellgast
Award Amount: $50,000.00
Abstract:
This project will develop an electrophoretic staining method for clotting factors. the method measures coagulation using a colorimetric system known as enzyme-linked coagulation assay (elca). elca is based on the simultaneous conversion of solid-phase-associated fibrinogen and enzyme-labeled… More

ULTRASENSITIVE IMMUNOASSAYS FOR CLOTTING FACTORS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Doellgast, George J , Principal Investigator
Award Amount: $50,000.00
Abstract:
We seek to develop an ultrasensitive immunoassay for peptides which are released during the activation of clotting factors. until now, the only activation peptide which has received widespread acceptance for clinical diagnosis is the fibrinopeptide a released when fibrinogen is converted to fibrin… More

ULTRASENSITIVE DETECTION OF TOXINS USING IMMUNOASSAY AMPLIFICATION

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: George J Doellgast Phd , Principal Investigator
Award Amount: $58,168.00

ULTRASENSITIVE DETECTION OF TOXINS USING IMMUNOASSAY AMPLIFICATION

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency / Branch: DOD / ARMY
Principal Investigator: George J Doellgast Phd , Principal Investigator
Award Amount: $476,926.00
Abstract:
The inability to detect toxins with adequate sensitivity is one of the principal reasons that they are potentially threatening, either due to "natural" exposure or deliberate and hostile use of these agents by an adversary. this proposal outlines a way that the detection of these toxins can be made… More

PURIFICATION OF A FIBRINOLYSIS ENHANCING PROTEIN

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark X Triscott
Award Amount: $50,000.00
Abstract:
During the development of our fibrinolytic assay system we noted an enhancement of fibrinolytic activity in plasma which could not be accounted for by any known fibrinolytic factor. using heparing affinity chromatography, with a 0.5m nac1 elution and an immuno affinity column we have been able to… More

NOVEL ACTIVITY AND IMMUNOASSAYS FOR PAI-1

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark X Triscott
Award Amount: $50,000.00
Abstract:
Plasminogen activation is modulated by a number of inhibitors. the fast acting inhibitor of t-pa and u-pa has been designated plasminogen activator inhibitor-1 (pai-1). the detection of raised levels of this acute phase protein is indicative of an imbalance in the hemostatic system. in order to… More

Novel Ultrasensitive Colorimetric Assay for DNA

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark X. Triscott
Award Amount: $50,000.00

Novel Ultrasensitive Colorimetric Assay for DNA

Award Year / Program / Phase: 1995 / SBIR / Phase II
Agency: HHS
Principal Investigator: Mark X. Triscott
Award Amount: $749,534.00
Abstract:
The detection of specific DNA sequences for the diagnosis of genetic diseases, cancer, and infectious disease is becoming increasingly widespread. A number of innovative techniques have been employed, including the oligonucleotide ligation assay and reverse dot-blot hybridization. The end-point, and… More

SYSTEM FOR SENSITIVE DETECTION OF BACTERIAL PATHOGENS

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Beard, G A
Award Amount: $100,000.00

AMPLIFIED CARD IMMUNOASSAY FOR DRUGS IN SALIVA

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Beard, G A
Award Amount: $100,000.00

AUTOLOGOUS ANTIBODIES IN OVARIAN CANCER

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Beard, Grady A
Award Amount: $100,000.00